Solvent effects on activity and conformation of plasminogen activator inhibitor-1

Thrombosis and Haemostasis

Volumn 81, Issue 3, 1999, Pages 407-414

  Andreasen, P A ^a   Egelund, R ^b   Jensen, S ^b   Rodenburg, K W ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DETERGENT; GLYCEROL; PAPAIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; SERINE PROTEINASE INHIBITOR; SOLVENT; TRITON X 100; TRYPSIN;

ARTICLE; CANCER CELL CULTURE; CONFORMATIONAL TRANSITION; ENZYME ACTIVITY; ENZYME SUBSTRATE; FIBROSARCOMA; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; TEMPERATURE;

EID: 0033018464     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614487     Document Type: Article

References (29)

1. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-60.
2. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
3. Andreasen PA, Kjøller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis. A review. Int J Cancer 1997; 72: 1-22.
4. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206.
5. 1-antitrypsin for structure and functions of serpins. Biochemistry 1989; 28: 8951-66.
6. Carrell RW, Stein PE. The biostructural pathology of the serpins: critical functions of sheet opening mechanism. Biol Chem Hoppe-Seyler 1996; 377: 1-17.
7. Lawrence DA. Ginsburg D, Day DE, Berkenpas MB, Verhamme IM, Kvassman JO, Shore JD. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
8. Wilczynska M, Fa M, Ohlsson PI, Ny T. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex. J Biol Chem 1995; 270: 29652-5.
9. Egelund R, Rodenburg KW, Andreasen PA, Rasmussen MS, Guldberg RE, Petersen TE. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 1998; 37: 6375-9.
10. Stratikos E, Gettins PGW. Major proteinase movement upon stable serpin-protease complex formation. Proc Natl Acad Sci USA 1997; 94: 453-8.
11. Wilczynska M, Fa M, Karolin, J, Ohlsson PI, Johansson LBÅ, Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat Struct Biol 1997; 4: 354-7.
12. Stein PE, Chothia C. Serpin tertiary structure transformation. J Mol Biol 1991; 221: 615-21.
13. Egelund R, Schousboe SL, Sottrup-Jensen L, Rodenburg KW, Andreasen PA. Type-1 plasminogen activator inhibitor. Conformational differences between latent, active, reactive-center-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur J Biochem 1997; 248: 775-85.
14. Plotnick MI, Mayne L, Schechter NM, Rubin H. Distortion of the active site of chymotrypsin complexed with a serpin. Biochemistry 1996; 35: 7586-90.
15. 1-proteinase inhibitor has an increased structural flexibility. FEBS Lett 1995; 370: 179-83.
16. Kaslik G, Kardos J, Szabo E, Szilagyi L, Zavodszky P, Westler WM, Markley JL, Graf L. Effects of serpin binding on the target proteinase: global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site. Biochemistry 1997; 36: 5455-64.
17. 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis. Biochemistry 1996; 35: 10608-15.
18. Gils A, Declerck PJ. Modulation of plasminogen activator inhibitor 1 by Triton X-100. Identification of two consecutive conformational transitions. Thromb Haemost 1998; 80: 286-91.
19. Kjøller L, Martensen PM, Sottrup-Jensen L, Justesen J, Rodenburg KW, Andreasen PA. Conformational changes of the reactive centre loop and β-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen activator inhibitor-1. Eur J Biochem 1996; 241: 38-46.
20. Munch M, Heegaard CW, Andreasen PA. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37.
21. Kjøller L, Kanse SM, Kirkegaard T. Rodenburg KW, Rønne E, Goodmann SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-9.
22. Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Danø K. Plasminogen activator inhibitor type 1: reactive center and ammo-terminal heterogeneity, determined by protein and cDNA sequencing. FEBS Lett 1986; 209: 213-8.
23. Groøndahl-Hansen J, Nielsen LS, Kristensen P, Grøndahl-Hansen V, Andreasen PA, Danø K. Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 1985; 113: 257-63.
24. Urano T, Strandberg L, Johansson LBÅ. Ny T. A substrate-like form of plasminogen activator inhibitor type 1. Eur J Biochem 1992; 209: 985-92.
25. Helenius A, Simons K. Solubilization of membranes by detergents. Biochim Biophys Acta 1975; 415: 29-79.
26. Gekko K, Timasheff SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol-water mixtures. Biochemistry 1981; 20: 4667-76.
27. Gekko K, Timasheff SN. Thermodynamic and kinetic examination of protein stabilization by glycerol. Biochemistry 1981; 20: 4677-86.
28. Hubbard SJ. Eisenmenger F, Thornton JM. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites. Protein Science 1994; 3: 757-68.
29. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-8.